Table 3.

Narcotic use of propensity score-matched cohorts by treatment group (N = 12,248).

	PCDF (N = 6124)	ACDF (N = 6124)	OR (95% CI)	P
Frequency of narcotic use
30-day narcotic use, n (%)	4208 (68.7)	4338 (70.8)	0.90 (0.83–0.98)	0.01
60-day narcotic use, n (%)	3990 (65.2)	4185 (68.3)	0.79 (0.79–0.94)	0.0002
90-day narcotic use, n (%)	3818 (62.3)	4055 (66.2)	0.84 (0.77–0.92)	<0.0001
120-day narcotic use, n (%)	3674 (60.0)	3943 (64.4)	0.83 (0.76–0.90)	<0.0001
Level of narcotic use
30-day mean MME, mg	1584.25	1384.64	1.19 (1.11–1.28)	<0.0001
60-day mean MME, mg	1601.76	1395.59	1.20 (1.12–1.28)	<0.0001
90-day mean MME, mg	1614.86	1402.07	1.21 (1.12–1.29)	<0.0001
120-day mean MME, mg	1624.52	1408.09	1.21 (1.13–1.29)	<0.0001

Data presented as n (%) unless otherwise indicated.

ACDF, anterior discectomy and fusion; CSM, cervical spondylotic myelopathy; MME, morphine milligram equivalent; PCDF, posterior decompression and fusion.